Analysts Offer Insights on Healthcare Companies: BeiGene Ltd (NASDAQ: BGNE), Sangamo Biosciences (NASDAQ: SGMO) and Xencor Inc (NASDAQ: XNCR)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BeiGene Ltd (NASDAQ: BGNE), Sangamo Biosciences (NASDAQ: SGMO) and Xencor Inc (NASDAQ: XNCR) with bullish sentiments.

BeiGene Ltd (NASDAQ: BGNE)

Cowen & Co. analyst Eric Schmidt assigned a Buy rating to BeiGene Ltd (NASDAQ: BGNE) on November 13. The company’s shares closed yesterday at $79.60.

According to TipRanks.com, Schmidt is a top 100 analyst with an average return of 39.2% and a 59.8% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Merrimack Pharmaceuticals, and Adaptimmune Therapeutics.

Currently, the analyst consensus on BeiGene Ltd is Moderate Buy and the average price target is $120, representing a 50.8% upside.

In a report released yesterday, Maxim Group also assigned a Buy rating to the stock with a $120 price target.
Sangamo Biosciences (NASDAQ: SGMO)

Cowen & Co. analyst Ritu Baral assigned a Buy rating to Sangamo Biosciences (NASDAQ: SGMO) on November 13. The company’s shares closed yesterday at $12.90.

Baral said:

“SGMO reported 3Q17 results and is on track to report first data from the Ph1/2 trials.”

According to TipRanks.com, Baral is a top 100 analyst with an average return of 23.4% and a 51.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Global Blood Therapeutics.

Sangamo Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $18.

Xencor Inc (NASDAQ: XNCR)

In a report issued on November 13, Arlinda Lee from Canaccord Genuity reiterated a Buy rating on Xencor Inc (NASDAQ: XNCR), with a price target of $36. The company’s shares closed yesterday at $20.29, close to its 52-week low of $18.55.

According to TipRanks.com, Lee is a 3-star analyst with an average return of 1.2% and a 39.9% success rate. Lee covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Actinium Pharmaceuticals, and Asterias Biotherapeutics.

Currently, the analyst consensus on Xencor Inc is Moderate Buy and the average price target is $35.50, representing a 75.0% upside.

In a report issued on November 12, Piper Jaffray also reiterated a Buy rating on the stock with a $35 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.